We are live on ! Find out more
KPRX icon

Kiora Pharmaceuticals
KPRX

15 hedge funds and large institutions have $517K invested in Kiora Pharmaceuticals in 2022 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 2 increasing their positions, 3 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

400% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 1

36% more funds holding

Funds holding: 11 → 15 (+4)

0.21% more ownership

Funds ownership: 6.36% → 6.57% (+0.21%)

33% less repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 3

57% less capital invested

Capital invested by funds: $1.22M → $517K (-$699K)

Holders
15
Holders Change
+4
Holders Change %
+36.36%
% of All Funds
0.24%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
2
Reduced
3
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
+$68K
2
E
Ergoteles
New York
+$12.8K
3
Goldman Sachs
Goldman Sachs
New York
+$9.67K
4
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$8.11K
5
TRCT
Tower Research Capital (TRC)
New York
+$7.58K

Top Sellers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
-$54.1K
2
Jane Street
Jane Street
New York
-$47K
3
UBS Group
UBS Group
Switzerland
-$14.6K
4
Osaic Holdings
Osaic Holdings
Arizona
-$261

KPRX Hedge Fund Activity: Q1 2022 in Review

15 of the 6,360 institutional investors tracked by Wall St. Rank reported a position in Kiora Pharmaceuticals (KPRX) for Q1 2022, worth a combined $517K — down 57% from $1.22M a quarter earlier.

Buyers outnumbered sellers: 5 funds opened new KPRX positions and 1 closed out — a net gain of 4 holders — while 2 added to existing stakes and 3 trimmed.

The largest buyer was Renaissance Technologies, opening a new position worth an estimated $68K. The largest seller was Vanguard Group, cutting an estimated $54.1K.

  • 15 institutional investors held Kiora Pharmaceuticals (KPRX) as of Q1 2022, up from 11 in Q4 2021.
  • Funds reported $517K of Kiora Pharmaceuticals stock for Q1 2022, down 57% quarter-over-quarter.
  • 5 funds opened new Kiora Pharmaceuticals positions in Q1 2022 and 1 closed out, a net change of +4 holders.
  • The largest Kiora Pharmaceuticals buyer in Q1 2022 was Renaissance Technologies, an estimated $68K added.
  • The largest Kiora Pharmaceuticals seller in Q1 2022 was Vanguard Group, an estimated $54.1K sold.

Based on aggregated 13F filings for Q1 2022.